Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 109

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 109
---
 authority’s review of such filings; |

| ● | adverse results from or delays in preclinical studies and clinical trials of our product candidates, including as a result of clinical holds, safety events, enrollment difficulties, or study protocol amendments; |

| ● | our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial; |

| ● | adverse regulatory decisions, including failure to receive regulatory approval of our drug to market for our product candidates; |

| ● | adverse developments concerning our manufacturers; |

| ● | our inability to obtain adequate product supply for any approved drug or inability to do so at acceptable prices; |

| ● | our inability to establish collaborations, if needed; |

| ● | our failure to commercialize our product candidates; |

| ● | additions or departures of key scientific or management personnel; |

| ● | unanticipated serious safety concerns related to the use of our product candidates; |

| ● | introduction of new drugs by our competitors; |

| ● | announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; |

| ● | any significant change in our management; |

| ● | our ability to effectively manage our growth; |

| ● | the size and growth of our initial target markets; |

| ● | actual or anticipated variations in quarterly operating results; |

| ● | our cash position; |

| ● | our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public; |

| ● | the public’s response to press releases or other public announcements by us or third parties, including our filings with the SEC; |

| ● | publication of research reports about us or our industry, or microbiome therapies in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts; |

| ● | guidance, if any, that we provide to the public, any changes in this guidance or our failure to meet this guidance; |

| ● | changes in the market valuations of similar companies; |

58

| ● | overall performance of the equity markets; |

| ● | sales of our Common Stock by us or our stockholders, in the future; |

| ● | trading volume of our Common Stock; |

| ● | investor perceptions of the investment opportunity associated with our Common Stock relative to other investment alternatives; |

| ● | actions by institutional or activist stockholders; |

| ● | change in accounting standards, policies, guidelines, interpretations or principles; |

| ●